Edition:
United States

Geron Corp (GERN.OQ)

GERN.OQ on NASDAQ Stock Exchange Global Select Market

5.49USD
4:00pm EDT
Change (% chg)

$0.08 (+1.48%)
Prev Close
$5.41
Open
$5.40
Day's High
$5.57
Day's Low
$5.34
Volume
839,285
Avg. Vol
1,174,225
52-wk High
$6.99
52-wk Low
$1.75

Chart for

About

Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc. (Janssen). The Company is engaged in the development of therapeutic products for oncology. Using its nucleic acid chemistry,... (more)

Overall

Beta: 2.57
Market Cap(Mil.): $993.40
Shares Outstanding(Mil.): 183.62
Dividend: --
Yield (%): --

Financials

  GERN.OQ Industry Sector
P/E (TTM): -- 103.50 32.14
EPS (TTM): -0.17 -- --
ROI: -19.53 1.52 12.66
ROE: -19.53 0.25 14.84

BRIEF-Geron Entered Into Market Issuance Agreement With B. Riley FBR

* GERON - ENTERED AT THE MARKET ISSUANCE SALES AGREEMENT WITH B. RILEY FBR TO ISSUE AND SELL ITS COMMON STOCK WITH OFFERING PRICE OF UP TO $100 MILLION Source http://bit.ly/2Is6vuy Further company coverage:

May 18 2018

BRIEF-Geron Reports Q1 Revenue $318,000

* GERON CORPORATION REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

May 10 2018

Competitors

Earnings vs. Estimates